Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Comparison of a Biolimus-Eluting Stent With a Sirolimus-Eluting Stent for Percutaneous Coronary Intervention

Next Previous
X
Search
Trial Profile

A Randomized Comparison of a Biolimus-Eluting Stent With a Sirolimus-Eluting Stent for Percutaneous Coronary Intervention

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Umirolimus (Primary) ; Sirolimus
  • Indications Acute coronary syndromes; Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis; Myocardial infarction; Myocardial ischaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms LEADERS
  • Sponsors Biosensors International Group

    • Most Recent Events

    • 21 May 2015 Results published in EuroPCR, as per Biosensors International Group media release.
    • 23 Oct 2012 Five-year results presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, according to a Biosensors International Group media release.
    • 27 Mar 2012 Pooled analysis presented at the 61st Annual Scientific Session of the American College of Cardiology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top